NA
CRNX icon

Neuburgh Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Neuburgh Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2K Hold
160
– – ﹤0.01% 919
2019
Q2 		$4K Hold
160
– – ﹤0.01% 910
2019
Q1 		$4K Buy
+160
New +$3.93K ﹤0.01% 907

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Neuburgh Advisers's CRNX Position: Q3 2019 in Review

Neuburgh Advisers held its Crinetics Pharmaceuticals (CRNX) position steady in Q3 2019 at 160 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Neuburgh Advisers first reported a position in CRNX in Q1 2019 and has held it in 3 quarters since. The position peaked at $4K in Q2 2019. 61 funds tracked by Wall St. Rank hold CRNX as of Q3 2019.

  • Neuburgh Advisers held 160 shares of Crinetics Pharmaceuticals worth $2K as of Q3 2019.
  • Neuburgh Advisers left its Crinetics Pharmaceuticals share count unchanged in Q3 2019.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #919 holding.
  • Neuburgh Advisers first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
  • Neuburgh Advisers's Crinetics Pharmaceuticals position peaked at $4K in Q2 2019.
  • 61 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.